FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310162912> ?p ?o ?g. }

• W4310162912 endingPage "2015" @default.
• W4310162912 startingPage "2014" @default.
• W4310162912 abstract "Background Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by the unique chromosome aberration t [(15;17) (q22; q21)]. APL has become highly curable with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, ATO must be administered intravenously. Patients need long hospital stay for consolidation therapy. Realgar-indigo naturalis formula (RIF), as a traditional Chinese regimen, is an oral arsenic compound. Previous clinical trials in China proved the efficacy and safety of RIF in patients with APL. (Hong-Hu Zhu et al. Lancet Oncol 2018;871-879). The combination of RIF and ATRA created homed-based manner for APL treatment. (Hong-Hu Zhu et al. Blood 2019;597-605) However, RIF is not widely used and still only available in China. More multicenter controlled trials are needed to prove the efficacy. In addition, it is inconvenient to administer ATO/RIF 4-weeks on 4-weeks off and ATRA 2-weeks on 2-weeks off. Since the combination of ATRA and ATO induces synergistic effects, we use ATRA and arsenic both in a 2-week on 2-week off regimen to assess if it will improve curative effects. Methods APL16 is an open-label, prospective, multicenter, noninferior, randomized clinical trial conducted in 3 hematological centers in China. We conducted this trial to evaluate whether oral realgar-indigo naturalis formula is noninferior to intravenous arsenic trioxide for non-high-risk patients with de novo APL. Eligible patients (n=81) with de novo APL have been enrolled. Patients were recruited between June 2016 and April 2022, with final follow-up in June 2022. All patients received induction therapy of ATRA 60mg/day (20-45 mg/m2/day) plus ATO (0.15 mg/kg/day). Then they were randomized to receive consolidation therapy including ATRA plus ATO or ATRA plus RIF. All patients received 6 cycles of ATRA/ATO or ATRA/RIF consolidation therapy in a 2-week on 2-week off regimen after achieving molecular complete remission. The primary end point of the study was event-free survival (EFS) at 2 years. The noninferiority margin for the difference of two arms in EFS was 5%. The secondary outcome of this trial is cumulative incidence of relapses and quality of life. Result Enrollment of 81 patients of this study was started in September 2016 and was completed in June 2020. 6 patients were excluded including one who refused to assign the informed consent, one who had acute coronary syndrome, two who had renal insufficiency and two who died before genetic diagnosis of PML-RARA fusion gene due to intracranial hemorrhage. 75 eligible patients were randomly assigned to ATRA-ATO group or ATRA-RIF group. Two patients in ATRA-ATO group did not receive assigned treatment but received ATRA plus RIF during entire consolidation therapy. The modified intention-to-treat analysis included all 75 patients who received at least one dose of the assigned therapy after randomisation. The baseline characteristics including age, sex, white blood cell and platelet counts at diagnosis, Sanz risk and PML breakpoint were not different between the two cohorts. Until the final follow-up, 68 patients have completed their planned courses of treatment. Median follow-up for the whole cohort was 24 months. All 75 patients achieved hematologic complete remission and continued to receive consolidation therapy. Patients in both arms achieved molecular complete remission after the second cycle of consolidation therapy. No relapses and deaths have been observed. The EFS at 2 years were 100% in both groups. Differentiation syndrome occurred in nine (12%) of 75 patients during induction therapy. The incidence of decrease of fibrinogen is higher in ATRA-ATO group than ATRA-RIF group during consolidation therapy (23.5% vs 2.9%, P= .032). No difference of adverse effects except this were observed between two groups. Conclusions: Interim results of this study proved efficacy of ATRA plus RIF was non-inferior to ATRA plus intravenous ATO for consolidation therapy in standard-risk APL. The toxicity is almost equivalent except slightly advantage of ATRA-RIF group on coagulation. No relapses may be attributed to simultaneous administer of ATRA and ATO/RIF. ATRA plus RIF offers a convenient and safe alternative for non-high-risk APL. Trial registration: The trial was registered in the Register.ClinicalTrial.gov with NCT02899169. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310162912 created "2022-11-30" @default.
• W4310162912 creator A5005791561 @default.
• W4310162912 creator A5010711856 @default.
• W4310162912 creator A5012677271 @default.
• W4310162912 creator A5018866860 @default.
• W4310162912 creator A5052282420 @default.
• W4310162912 creator A5057325735 @default.
• W4310162912 creator A5085642649 @default.
• W4310162912 creator A5087446982 @default.
• W4310162912 date "2022-11-15" @default.
• W4310162912 modified "2023-09-28" @default.
• W4310162912 title "Oral Realgar-<i>Indigo Naturalis</i> Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16" @default.
• W4310162912 doi "https://doi.org/10.1182/blood-2022-166635" @default.
• W4310162912 hasPublicationYear "2022" @default.
• W4310162912 type Work @default.
• W4310162912 citedByCount "0" @default.
• W4310162912 crossrefType "journal-article" @default.
• W4310162912 hasAuthorship W4310162912A5005791561 @default.
• W4310162912 hasAuthorship W4310162912A5010711856 @default.
• W4310162912 hasAuthorship W4310162912A5012677271 @default.
• W4310162912 hasAuthorship W4310162912A5018866860 @default.
• W4310162912 hasAuthorship W4310162912A5052282420 @default.
• W4310162912 hasAuthorship W4310162912A5057325735 @default.
• W4310162912 hasAuthorship W4310162912A5085642649 @default.
• W4310162912 hasAuthorship W4310162912A5087446982 @default.
• W4310162912 hasBestOaLocation W43101629121 @default.
• W4310162912 hasConcept C104317684 @default.
• W4310162912 hasConcept C126322002 @default.
• W4310162912 hasConcept C141071460 @default.
• W4310162912 hasConcept C168563851 @default.
• W4310162912 hasConcept C178790620 @default.
• W4310162912 hasConcept C185592680 @default.
• W4310162912 hasConcept C197934379 @default.
• W4310162912 hasConcept C2776601000 @default.
• W4310162912 hasConcept C2780386689 @default.
• W4310162912 hasConcept C2781121885 @default.
• W4310162912 hasConcept C502230775 @default.
• W4310162912 hasConcept C55493867 @default.
• W4310162912 hasConcept C61943457 @default.
• W4310162912 hasConcept C71924100 @default.
• W4310162912 hasConcept C90924648 @default.
• W4310162912 hasConceptScore W4310162912C104317684 @default.
• W4310162912 hasConceptScore W4310162912C126322002 @default.
• W4310162912 hasConceptScore W4310162912C141071460 @default.
• W4310162912 hasConceptScore W4310162912C168563851 @default.
• W4310162912 hasConceptScore W4310162912C178790620 @default.
• W4310162912 hasConceptScore W4310162912C185592680 @default.
• W4310162912 hasConceptScore W4310162912C197934379 @default.
• W4310162912 hasConceptScore W4310162912C2776601000 @default.
• W4310162912 hasConceptScore W4310162912C2780386689 @default.
• W4310162912 hasConceptScore W4310162912C2781121885 @default.
• W4310162912 hasConceptScore W4310162912C502230775 @default.
• W4310162912 hasConceptScore W4310162912C55493867 @default.
• W4310162912 hasConceptScore W4310162912C61943457 @default.
• W4310162912 hasConceptScore W4310162912C71924100 @default.
• W4310162912 hasConceptScore W4310162912C90924648 @default.
• W4310162912 hasIssue "Supplement 1" @default.
• W4310162912 hasLocation W43101629121 @default.
• W4310162912 hasOpenAccess W4310162912 @default.
• W4310162912 hasPrimaryLocation W43101629121 @default.
• W4310162912 hasRelatedWork W2287670947 @default.
• W4310162912 hasRelatedWork W2382005073 @default.
• W4310162912 hasRelatedWork W2573470391 @default.
• W4310162912 hasRelatedWork W2889022305 @default.
• W4310162912 hasRelatedWork W2979597473 @default.
• W4310162912 hasRelatedWork W3028606419 @default.
• W4310162912 hasRelatedWork W3032531242 @default.
• W4310162912 hasRelatedWork W3143468013 @default.
• W4310162912 hasRelatedWork W33403106 @default.
• W4310162912 hasRelatedWork W4310162912 @default.
• W4310162912 hasVolume "140" @default.
• W4310162912 isParatext "false" @default.
• W4310162912 isRetracted "false" @default.
• W4310162912 workType "article" @default.